TYRX is a value-based offering aimed at lowering infection risk and reducing readmission rates with the long-term goal of creating better outcomes.
India Medtronic launched TYRX Absorbable Antibacterial Envelope (TYRX Envelope), an absorbable, single-use, antibacterial envelope designed to stabilize a cardiac implantable electronic device (CIED) or implanted neurostimulator while releasing antimicrobial agents over a minimum of seven days. Constructed from a multifilament, knitted absorbable mesh, the TYRX Envelope holds the CIED device and is fully absorbed by the body approximately nine weeks after implantation. It can be used with any implantable defibrillator, pacemaker, or neurostimulator.
Annually in India, 50,000 people with heart conditions receive a CIED, such as a pacemaker or implantable cardioverterdefibrillator (ICD), to help manage abnormal heart rhythms. As with any surgical procedure, there is a
risk for infection due to bacteria being introduced at the time of implantation. The current standard of care for CIED infection treatment includes complete system removal/replacement and prolonged antibiotic therapy.
“TYRX is a value-based offering aimed at lowering infection risk and reducing readmission rates with the long-term goal of creating better outcomes,” says Abhishek Bhargava, director, Cardiac Rhythm Management, Cardiac Ablation and Diagnostics at Medtronic India. CIED infections occur in 1-4% of all CIED patients and are associated with substantially increased morbidity, mortality, and cost.
The TYRX Envelope was cleared by the FDA in 2013 and received CE Mark in 2014. In 2019, the European Heart Rhythm Association (EHRA) issued an international consensus document on how to prevent, diagnose and treat CIED infections.
